Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Enters the Race to Develop New COVID-19 Treatments

By Cory Renauer – Jun 5, 2020 at 12:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharmaceutical giant is working with several partners on a monoclonal antibody treatment for the novel coronavirus.

Another big biopharmaceutical company has joined the crowd working to develop effective treatments for COVID-19. AbbVie (ABBV -2.12%) has partnered with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop 47D11, an antibody that blocks the SARS-CoV-2 coronavirus that causes COVID-19.   

To treat and prevent

AbbVie's partners made waves in May with a paper describing 47D11 and its ability to neutralize SARS-CoV-2. In a laboratory, the antibody latched onto the spike protein that's essentially the key that SARS-CoV-2 uses to enter a host's cells. If 47D11 can safely do the same thing to the virus in humans, it could be used as a treatment for COVID-19 or as a post-exposure measure to prevent people from becoming ill.

Gloved hand holding coronavirus blood vial.

Image source: Getty Images.

While AbbVie and its partners are working at a remarkable pace, there is no data from animal studies of 47D11 yet. Pushed along by the company's vast resources, preclinical studies will progress quickly, but we still don't know when researchers will be ready to start human clinical trials of 47D11.

Late entry

At this point, at least two experimental antibodies that target SARS-CoV-2 are far ahead of 47D11 in the development cycle. Regeneron (REGN -1.85%) plans to begin clinical trials with REGN-COV2, an antibody cocktail comprised of two or three proteins that work in concert, later this month.

And Eli Lilly (LLY 0.35%) began dosing actual COVID-19 patients with its experimental treatment, LY-CoV555, earlier this week. LY-CoV555 is a monoclonal antibody developed from antibodies that were isolated from one of the first U.S. patients to recover from COVID-19.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$140.29 (-2.12%) $-3.04
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$332.95 (0.35%) $1.17
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$731.86 (-1.85%) $-13.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.